Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas

NCT00003718 is registered in ClinicalTrials.gov with Herbert Irving Comprehensive Cancer Center as lead sponsor.

NCT NCT00003718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 1998
Completion date
Not reported
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, ovarian cancer, sarcoma